Conference on Innovations in Tuberculosis 2024

To stay updated on the relevant developments, make sure you are signed up for our newsletter. 

Tuberculosis (TB) caused 1.6 million deaths in 2021, being the leading cause of death among infectious diseases, above HIV. Yet, it is a curable and preventable disease. While a quarter of the global population has been infected, only 5-10 % of infected individuals develop symptoms. The highest burden regions are South-East Asia, Africa, and the Western Pacific. This bacterial disease is treated by a long course of antibiotics. Nevertheless, for Multidrug-resistant TB (MDR-TB) treatment options are limited, and MDR-TB remains a public health crisis and a health security threat.

TB is a priority on the global health agenda. Orchestrated actions of national and global leadership, researcher organizations, and civil societies strive to achieve a world free of TB. Towards this goal, equitable access to prevention, testing, treatment, and care remains a challenge. On the other hand, we are witnessing encouraging new tools to curb TB. A recent study demonstrated a remarkable reduction in TB transmission due to nutritional supplements offered to household contacts, providing an evidence-based approach to intervene with structural determinants of TB, such as malnutrition. On the biomedical side, a historical milestone seems to be within close range, with the late-stage clinical evaluation of a vaccine to prevent a pulmonary form of TB in adolescents and adults, developed by the Gates Foundation. In parallel, new treatment guidelines on 6-month all-oral regimens for MDR-TB offer simplified treatment options for those patients.   

Yet these exciting developments and innovations are mainly discussed at major international meetings. This, in turn, offers limited space for researchers and healthcare professionals from high-burden countries in Africa, and restricts discussions tailored to regional epidemiological situations, healthcare, and societal contexts. To this end, we propose a platform to disseminate clinically relevant innovations and discuss their translation and implementation in Africa, considering region-specific epidemic patterns, available prevention, testing and treatment options, and healthcare settings.

General Information 

Practical Information 

If you are eligible for a discount, please contact the conference secretariat Yulia Veldhuis at yulia.veldhuis@amededu.com for the special registration code.

*Countries included in the low-income and middle-income economies list of the World Bank Classification

Important

• We strongly advise that you register early to ensure your registration. Registration will close when the capacity of the venue is reached.

• Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

• The Conference on Innovations in Tuberculosis accepts new original data as well as encored abstracts. All abstracts must focus on the African region and contain up-to-date information at the time of the conference. 

• Registration fees are waived for early-career professionals with an accepted abstract. A 50% discount is offered to early-career professionals without an accepted abstract.The requirements for the application are specified here.

• Abstract submitters are strongly encouraged to use person-first language in their abstracts. View the video tutorial and guidelines here.

By submitting an abstract to a meeting organized by Virology Education BV (VE), the abstract submitter hereby agrees to the terms and conditions.

The terms and conditions can be viewed here.  

The members of Scientific Committee are hand-picked by the Organizing Committee (OC) and the conference secretariat based on their significant contributions and commitment to the field. They assist the OC by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

• Amsalu Bekele Binegdie, MD, College of Health Sciences, Addis Ababa University, Ethiopia
• John Bimba, PhD, Bingham University, Nigeria
• Maryline Bonnet, MD, PhD, The French National Research Institute for Sustainable Development (IRD), the University of Montpellier and the National Institute of Health and Medical Research, Montpellier, France, Mbarara University of Science and Technology in MBarara, Uganda 
• Jeremiah Chakaya Muhwa, MBChB, MMeD, DThM, Kenyatta University, Respiratory Society of Kenya, Kenya 
• Novel Chegou, BMLS (Hons), BSc. Hons., PhD, Stellenbosch University, South African Medical Research Council Centre for Tuberculosis Research, Stellenbosch University, South Africa
• Joel Fleury Djoba Siawaya, PhD, HDR, Mother and Child University Hospital, Gabon
• Thandi J.N Dlamini-Miti, MBBCh, Msc, Isango Lethemba TB Research Unit, University of the Witwatersrand, South Africa
• Alberto García-Basteiro, MD, PhD, Barcelona Institute for Global Health (ISGlobal), Spain, Centro de Investigação em Saúde de Manhiça (CISM), Mozambique
• Norbert Heinrich, MD, LMU University Hospital, Division of Infectious Diseases and Tropical Medicine, Germany
• Bouke de Jong, MD, PhD, Institute of Tropical Medicine, Belgium
• Celso Khosa, MD, PhD, Instituto Nacional de Saúde, Mozambique
• Andre Loxton, PhD, SAMRC and Stellenbosch University, South Africa
• Sayoki G Mfinanga, MD,PhD, Liverpool School Tropical Medicine, University Collage London, England, Nelson Mandela African Institution of Science and Technology (NM-AIST), The Muhimbili University of Health and Allied Sciences, Tanzania
• Lloyd Mulenga, BScHb, MBChB, MSc, MMed, PhD, Ministry of Health, Zambia
• Esther Stanslaus Ngadaya, MD, PGDHE, PhD, National Institute for Medical Research (NIMR), Kampala National University, Tanzania
• Abel Nkolo, MBChB, MPH, PhD, Africa and LAC Region, Uganda
• Nyanda Elias Ntinginya, MD, Msc, PhD, National Institute for Medical Research (NIMR), Tanzania
• Issa Sabi, MD, MMed, PhD, Mbeya Medical Research Center, National Institute for Medical Research (NIMR), Tanzania
• Simon Walusimbi, MD, MSc, PhD, Makerere University School of Public Health and Lung Institute, Uganda

Support Our Initiative
Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in the Conference on Innovations in Tuberculosis.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored
support package by contacting Kim Go at kim.go@amededu.com.
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

• Symposium opportunities
• Non-commercial interviews with company representatives
• Verbal acknowledgement during the program 
• Discounted and complimentary registrations for your representatives
• Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
• Company acknowledgement on printed meeting materials including but not limited to banners and the program book
• Digital and printed advertising opportunities 
• Social media shout-outs
• Logo on the conference bag 

 
*Subject to the support level.